MedPal AI plc (AIM: MPAL) has announced that its New Health business has become one of the UK’s top 30 Mounjaro providers by supply volume, climbing from 3,048th to 29th
MedPal AI Strengthens Board as £28m Revenue Run Rate Drives Growth Incentive Package
MedPal AI plc (AIM: MPAL; FRA: Z1N) has appointed former eEnergy Group chief executive Harvey Sinclair as an independent non-executive director as the digital health group looks to strengthen its
MedPal AI plc – From zero to £28 million annualised in ten months
MedPal AI plc (AIM: MPAL) has reported a sharp acceleration in trading, with its New Health GLP-1 weight-management business generating £1.83 million of revenue in August, an increase of more
Mounjaro wins US approval to cut heart attack and stroke risk
MedPal AI plc (AIM: MPAL) has highlighted the potential expansion of the GLP-1 market after the US Food and Drug Administration approved Eli Lilly’s Mounjaro to reduce the risk of
MedPal highlights new UK oral weight-loss treatment
MedPal AI plc (AIM: MPAL) has highlighted the UK approval of Eli Lilly’s once-daily oral GLP-1 treatment, Foundayo, which has been authorised for weight loss and weight maintenance in eligible